Description: The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.

Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Further Key Findings from the Study Suggest:

The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D

Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment

Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors

On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer

Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth

North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine

Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.
2.5 Industry analysis - Porter's
2.6 Next Generation Cancer Diagnostics PESTEL Analysis

3 Next Generation Cancer Diagnostics Technology Outlook
3.1 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
3.2 NGS-based cancer diagnostics
3.2.1 NGS-based cancer diagnostics market, 2013 - 2024 (USD Million)
3.3 qPCR & Multiplexing
3.3.1 qPCR & multiplexing-based market, 2013 - 2024 (USD Million)
3.4 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
3.4.1 LOAC & RT-PCR-based market, 2013 - 2024 (USD Million)
3.5 Protein microarrays-based cancer diagnostics
3.5.1 Protein microarrays market, 2013 - 2024 (USD Million)
3.6 DNA microarrays-based cancer diagnostics
3.6.1 DNA microarrays-based cancer diagnostics market, 2013 - 2024 (USD Million)

4 Next Generation Cancer Diagnostics Outlook by Cancer Type
4.1 Global next generation cancer diagnostics revenue share, by cancer type, 2015 & 2024
4.2 Lung cancer
4.2.1 NGCD for lung cancer market, 2013 - 2024 (USD Million)
4.3 Breast cancer
4.3.1 NGCD for breast cancer market, 2013 - 2024 (USD Million)
4.4 Colorectal cancer
4.4.1 NGCD for colorectal cancer market, 2013 - 2024 (USD Million)
4.5 Cervical cancer
4.5.1 NGCD for cervical cancer market, 2013 - 2024 (USD Million)
4.6 Other types of cancer
4.6.1 NGCD for other forms of cancer market, 2013 - 2024 (USD Million)

5 Next Generation Cancer Diagnostics Outlook by Application Outlook
5.1 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
5.2 Biomarker development
5.2.1 NGCD for biomarker development market, 2013 - 2024 (USD Million)
5.3 CTC analysis
5.3.1 NGCD for CTC analysis market, 2013 - 2024 (USD Million)
5.4 Proteomic analysis
5.4.1 NGCD for proteomic analysis market, 2013 - 2024 (USD Million)
5.5 Epigenetic analysis
5.5.1 NGCD for epigenetic analysis market, 2013 - 2024 (USD Million)
5.6 Genetic analysis
5.6.1 NGCD for genetic analysis market, 2013 - 2024 (USD Million)

6 Next Generation Cancer Diagnostics Outlook by Function
6.1 Global next generation cancer diagnostics revenue share, by function, 2015 & 2024
6.2 Therapeutic monitoring
6.2.1 NGCD for therapeutic monitoring market, 2013 - 2024 (USD Million)
6.3 Companion diagnostics
6.3.1 NGCD for companion diagnostics market, 2013 - 2024 (USD Million)
6.4 Prognostic diagnostics
6.4.1 NGCD for prognostics market, 2013 - 2024 (USD Million)
6.5 Cancer screening
6.5.1 NGCD for cancer screening market, 2013 - 2024 (USD Million)
6.6 Risk analysis
6.6.1 NGCD for risk analysis market, 2013 - 2024 (USD Million)

7 Next Generation Cancer Diagnostics Regional Outlook
7.1 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
7.2 North America
7.2.1 North America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.2.3 Canada
7.2.3.1 Canada next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.3 Europe
7.3.1 Europe next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.3.2 Germany
7.3.2.1 Germany next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.3.3 France
7.3.3.1 France next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.4.2 Japan
7.4.2.1 Japan next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.4.3 China
7.4.3.1 China next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.5 Latin America
7.5.1 Latin America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.6 MEA
7.6.1 MEA next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa next generation cancer diagnostics market, 2013 - 2024 (USD Million)

8 Competitive Landscape
8.1 Janssen Global Services, LLC
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 F. Hoffmann-La Roche Ltd
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Koninklijke Philips N.V.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Abbott
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.6 GE Healthcare
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Thermo Fisher Scientific, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Agilent Technologies (Dako)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Illumina, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Qiagen
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
8.11 Cepheid
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
8.12 Opko Health, Inc.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Service Benchmarking
8.12.4 Strategic Initiatives
8.13 Hologic, Inc (Gen-Probe)
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Product Benchmarking
8.13.4 Strategic Initiatives
8.14 Perkin Elmer, Inc.
8.14.1 Company Overview
8.14.2 Financial Performance
8.14.3 Product Benchmarking
8.14.4 Strategic Initiatives
8.15 Sysmex Corporation
8.15.1 Company Overview
8.15.2 Financial Performance
8.15.3 Product Benchmarking
8.15.4 Strategic Initiatives
8.16 Myriad Genetics, Inc.
8.16.1 Company Overview
8.16.2 Financial Performance
8.16.3 Product Benchmarking
8.16.4 Strategic Initiatives
8.17 Almac Group
8.17.1 Company Overview
8.17.2 Financial Performance
8.17.3 Product Benchmarking
8.17.4 Strategic Initiatives
8.18 Exosome Diagnostics, Inc.
8.18.1 Company Overview
8.18.2 Financial Performance
8.18.3 Product Benchmarking
8.18.4 Strategic Initiatives
8.19 Genomic Health, Inc.
8.19.1 Company Overview
8.19.2 Financial Performance
8.19.3 Product Benchmarking
8.19.4 Strategic Initiatives

List of Tables

Table 1 Next Generation Cancer Diagnostics - Industry Snapshot & Key Buying Criteria, 2013 - 2024
Table 2 Global next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 3 Global next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 4 Global next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 5 Global next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 6 Global next generation cancer diagnostics market, by region 2013 - 2024 (USD Million)
Table 7 Next generation cancer diagnostics key market driver analysis
Figure 1 Next generation cancer diagnostics market segmentation

List of Figures

Table 66 South Africa next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 65 South Africa next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 64 South Africa next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 63 South Africa next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 62 MEA next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 61 MEA next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 60 MEA next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 59 MEA next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 58 Brazil next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 57 Brazil next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 56 Brazil next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 55 Brazil next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 54 Latin America next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 53 Latin America next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 52 Latin America next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 51 Latin America next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 50 China next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 49 China next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 48 China next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 47 China next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 46 Japan next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 45 Japan next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 44 Japan next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 43 Japan next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 42 Asia Pacific next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 41 Asia Pacific next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 40 Asia Pacific next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 39 Asia Pacific next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 38 France next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 37 France next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 36 France next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 35 France next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 34 Germany next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 33 Germany next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 32 Germany next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 31 Germany next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 30 Europe next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 29 Europe next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 28 Europe next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 27 Europe next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 26 Canada next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 25 Canada next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 24 Canada next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 23 Canada next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 22 U.S. next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 21 U.S. next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 20 U.S. next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 19 U.S. next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 18 North America next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
Table 17 North America next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
Table 16 North America next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
Table 15 North America next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
Table 14 Next generation cancer diagnostics key market restraint analysis
Table 13 Australia and New Zealand cancer incidence in 2012
Table 12 Africa cancer incidence, 2012
Table 11 Asia cancer incidence, 2012
Table 10 Europe cancer incidence, 2012
Table 9 North America cancer incidence in 2012
Table 8 Global cancer incidence, 2012

List of Figures

Figure 1 Next generation cancer diagnostics market segmentation
Figure 2 Global next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 3 Next generation cancer diagnostics market dynamics
Figure 4 Cost per raw mega base (Mb) of DNA sequence
Figure 5 Cost per genome sequencing
Figure 6 Key opportunities prioritized, 2015 & 2024
Figure 7 Next generation cancer diagnostics market Porter's analysis
Figure 8 Next generation cancer diagnostics market PESTEL analysis
Figure 9 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
Figure 10 NGS-based cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 11 qPCR & Multiplexing based market, 2013 - 2024 (USD Million)
Figure 12 LOAC & RT-PCR-based market, 2013 - 2024 (USD Million)
Figure 13 Protein microarrays market, 2013 - 2024 (USD Million)
Figure 14 DNA microarrays-based cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 15 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
Figure 16 NGCD for lung cancer market, 2013 - 2024 (USD Million)
Figure 17 NGCD for breast cancer market, 2013 - 2024 (USD Million)
Figure 18 NGCD for colorectal cancer market, 2013 - 2024 (USD Million)
Figure 19 NGCD for cervical market, 2013 - 2024 (USD Million)
Figure 20 NGCD for other forms of cancer market, 2013 - 2024 (USD Million)
Figure 21 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
Figure 22 NGCD for biomarker development market, 2013 - 2024 (USD Million)
Figure 23 NGCD for CTC analysis market, 2013 - 2024 (USD Million)
Figure 24 NGCD for proteomic analysis market, 2013 - 2024 (USD Million)
Figure 25 NGCD for epigenetic analysis market, 2013 - 2024 (USD Million)
Figure 26 NGCD for genetic analysis market, 2013 - 2024 (USD Million)
Figure 27 Global next generation cancer diagnostics revenue share, by function, 2015 & 2024
Figure 28 NGCD for therapeutic monitoring market, 2013 - 2024 (USD Million)
Figure 29 NGCD for companion diagnostics market, 2013 - 2024 (USD Million)
Figure 30 NGCD for prognostics market, 2013 - 2024 (USD Million)
Figure 31 NGCD for cancer screening market, 2013 - 2024 (USD Million)
Figure 32 NGCD for risk analysis market, 2013 - 2024 (USD Million)
Figure 33 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
Figure 34 North America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 35 Estimated number of new cancer cases and deaths in the U.S., 2015
Figure 36 U.S. next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 37 Canada next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 38 Europe next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 39 Germany next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 40 France next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 41 Asia Pacific next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 42 Japan next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 43 China next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 44 Latin America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 45 Brazil next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 46 MEA next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Figure 47 South Africa next generation cancer diagnostics market, 2013 - 2024 (USD Million)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4076509/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024
Web Address: http://www.researchandmarkets.com/reports/4076509/
Office Code: SC2GPOL1

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 7950</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 9950</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: _________________________________________
Email Address: * _______________________________________
Job Title: ___________________________________________
Organisation: _________________________________________
Address: ____________________________________________
City: _________________________________________________
Postal / Zip Code: ____________________________________
Country: ____________________________________________
Phone Number: ________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083310383
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World